FDA panel focus on LST (late-stent thrombosis) is likely to soften DES (drug-eluting stent) penetration of US market
This article was originally published in Clinica
Executive Summary
The two-day FDA panel meeting on the safety of drug-eluting stents, which will start tomorrow and end on Friday December 8 (after Clinica's weekly issue, No 1235, goes to press), is the latest chapter in a year of ever-more intense scrutiny of current and prospective players in the $6bn US market DES market.